© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Tayside DD1 9SY, Dundee, UK
* Corresponding author. Tel.: +44-1382-632574; fax: +44-1382-644972. a.d.struthers{at}dundee.ac.uk
Aldosterone is well recognized as a cause of sodium reabsorption, water retention, and potassium and magnesium loss; however, it also produces a variety of other actions that lead to progressive target organ damage in the heart, vasculature, and kidneys. Aldosterone interacts with mineralocorticoid receptors to promote endothelial dysfunction, facilitate thrombosis, reduce vascular compliance, impair baroreceptor function, and cause myocardial and vascular fibrosis. Although angiotensin II has been considered the major mediator of cardiovascular damage, increasing evidence suggests that aldosterone may mediate and exacerbate the damaging effects of angiotensin II. While angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers reduce plasma aldosterone levels initially, aldosterone rebound, or ‘escape’ may occur during long-term therapy. Therefore, aldosterone blockade is required to reduce the risk of progressive target organ damage in patients with hypertension and heart failure. This may be achieved nonselectively with spironolactone or with use of the selective aldosterone blocker eplerenone. While both agents have been demonstrated to be effective antihypertensive agents, eplerenone may produce improved target organ protection as witnessed in a variety of clinical settings, without the antiandrogenic and progestational effects commonly observed with spironolactone.
KEYWORDS Heart failure; Target organ damage; Aldosterone; Angiotensin II; Spironolactone; Eplerenone
Time for primary review 20 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1511 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fang, D. G. Oreopoulos, and J. M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol. Dial. Transplant., June 20, 2008; (2008) gfn321v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C Shah, S. Pringle, and A. Struthers Aldosterone Blockade Over and Above ACE-Inhibitors in Patients with Coronary Artery Disease but without Heart Failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 20 - 30. [Abstract] [PDF]
|
|